XML 75 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events - Additional Information (Detail) - USD ($)
12 Months Ended
Jan. 28, 2019
Dec. 31, 2018
Maximum    
Subsequent Event [Line Items]    
Milestone payables   $ 1,000,000,000
Voyager Therapeutics | Collaboration and License Agreement    
Subsequent Event [Line Items]    
Collaborative arrangement right description   Under the terms of the agreement, on a program-by-program basis, upon the achievement of milestones or metrics specified in the agreement for VY-AADC and VY-FXN01, Voyager will have the option to co-develop and co-commercialize such program with the Company in the U.S. under cost- and profit-sharing arrangements, and Voyager agrees to forfeit certain milestones and royalties related to such program for which Voyager has exercised its co-develop and co-commercialize option.
Voyager Therapeutics | Subsequent Event | Collaboration and License Agreement    
Subsequent Event [Line Items]    
Up-front cash payable $ 115,000,000  
Collaborative agreement equity investment amount 50,000,000  
Voyager Therapeutics | Subsequent Event | Collaboration and License Agreement | Development, Regulatory and Commercial Milestone Payment | Maximum    
Subsequent Event [Line Items]    
Milestone payables $ 1,700,000,000